# A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)

> **NCT06122831** · PHASE1,PHASE2 · RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 92 (estimated)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** TQ05105 Tablets
- **DRUG:** TQB3617 Capsules

## Key facts

- **NCT ID:** NCT06122831
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-12
- **Primary completion:** 2026-12
- **Final completion:** 2027-04
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06122831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06122831, "A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06122831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*